logo
Fairexpay and PhysicsWallah's Acadfly Partner to Provide Student Remittances for Overseas Education

Fairexpay and PhysicsWallah's Acadfly Partner to Provide Student Remittances for Overseas Education

NewsVoir
New Delhi [India], June 25: In an attempt to change the way students transfer funds for education and living expenses abroad, Fairexpay has partnered with Acadfly, the study-abroad program of PhysicsWallah. This partnership will try to digitalise the remittance journey to make international money transfers easier and cost-effective for students and their families.
Outward remittances under the Liberalised Remittance Scheme (LRS) for resident individuals studying abroad amounted to US$ 3,500 million during the fiscal year 2023-24. This figure is expected to grow further in the coming year, as increasing number of Indian students may be opting for international education and rising tuition and living costs abroad.
A number of these students face significant hurdles in sending money abroad. Common issues include multiple visits to banks, forex costs, several to-and-fro documentation, and delays in processing, adding unnecessary stress to students and their families, impacting their overall study abroad experience.
Fairexpay, with its expertise in cross-border remittances, wants to leverage Acadfly's student outreach to enable students to remit tuition fees and living expenses with less effort via a platform that aims to ensure compliance, speed, and lower costs, which may eliminate hidden charges and try to cut down on long processing times.
"We are thrilled to collaborate with Acadfly in trying to reshape the student remittance ecosystem. This partnership will try to not only simplify the remittance process but also help students save on forex costs, making education more accessible even globally," said Saurabh Jain, CBO at Fairexpay.
This move will try to align with Acadfly's attempt at trying to provide end-to-end solutions for students and help to make their international education journey as seamless as possible.
"At Acadfly, we try to enhance the student experience. By partnering with Fairexpay, we are trying to offer a streamlined, cost-efficient, and hassle-free remittance solution that will also try to align with our attempt to support students pursuing education abroad," said Gaurav Kumar, Associate Vice President at Acadfly, the study-abroad program of PhysicsWallah.
With Fairexpay's platform and Acadfly's student outreach, this partnership is trying to provide not just convenience but also cost savings, reinforcing both companies' attempts to provide innovation and financial empowerment in the education sector.
Fairexpay is a leading financial technology company specializing in digital payment solutions that enable seamless, secure, and cost-effective cross-border transactions. With a focus on innovation and customer experience, Fairexpay is committed to breaking down barriers in international finance through its state-of-the-art digital platform.
PhysicsWallah (PW), an education platform, was founded in 2020 by Alakh Pandey and Prateek Maheshwari. Headquartered in Noida, Uttar Pradesh, PW aims to democratize education through online, offline and hybrid platforms. Initially launched as a YouTube channel in 2016, PW now offers education to students through its YouTube channels, including vernacular languages. PW aims to create a hybrid education ecosystem in the country by establishing tech-enabled offline and hybrid centres in cities nationwide. PW's offerings span various educational segments, including test preparation, a skilling vertical, higher education, and education abroad. PW has raised funding from investors, including Hornbill Capital, Lightspeed Ventures, Westbridge and GSV Ventures.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Torrent Pharma to acquire JB Pharma from KKR at ₹25,689 cr valuation
Torrent Pharma to acquire JB Pharma from KKR at ₹25,689 cr valuation

Business Standard

time41 minutes ago

  • Business Standard

Torrent Pharma to acquire JB Pharma from KKR at ₹25,689 cr valuation

In one of the largest pharma deals in the domestic market in recent years, Ahmedabad-based Torrent Pharmaceuticals will acquire a controlling stake in investment firm KKR-backed JB Chemicals and Pharmaceuticals (known as JB Pharma) at an equity valuation of ₹25,689 crore, which will be followed by the merger of the two entities. The deal will be executed in two phases — acquisition of the 46.39 per cent stake held by KKR in JB Pharma at ₹1,600 per share, amounting to ₹11,917 crore, followed by a mandatory open offer to acquire up to 26 per cent of JB Pharma shares from public shareholders at ₹1,639.18 per share. 'In addition to the above, Torrent has also expressed its intent to acquire up to 2.8 per cent of equity shares from certain employees of JB Pharma at the same price per share as KKR,' the company said in a statement on Sunday. The next step in the deal will be a merger between Torrent Pharma and JB Pharma through a scheme of arrangement, under which every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharma. The boards of directors of both companies have approved this arrangement. KKR had acquired 54 per cent of JB Pharma in July 2020 from the promoters and founders, the Mody family, for approximately ₹3,100 crore (or ₹745 per share). It sold a part of its stake in March this year through block deals for ₹1,459.8 crore. KKR has earned more than five times on its investment, with around 36 per cent gross IRR. For instance, Torrent Pharma has previously indicated plans to increase its medical representative (MR) strength by 23 per cent by the end of FY26, and the acquisition can aid in manpower augmentation. Torrent Pharma holds a 3.74 per cent share in the domestic market (according to Pharmarack, May 2025), while JB Pharma commands a 1.12 per cent share. Further, consolidation in key international markets is expected to offer greater scalability. Samir Mehta, executive chairman of Torrent Pharma, said they want to build on JB Pharma's heritage and platform for the future. 'Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint, offer immense potential to scale both revenue and profitability. This strategic alignment furthers our goal of strengthening our presence in the Indian pharma market and builds a larger diversified global presence. Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent.' Torrent has previously taken the inorganic route to grow its business and enter newer segments — in 2013, it acquired Elder Pharma's India-branded business; followed by the dermaceutical business of Zyg Pharma in 2015 and the API plant of Glochem Industries in 2016. Among other major deals, it bought the India-branded business of Unichem in 2017. Its last major acquisition was of skin-care products from Curatio Healthcare in 2022. Torrent Pharma is a highly domestic-focused company, drawing around 55 per cent of its consolidated revenues from the domestic formulations business. India sales grew by 13 per cent in FY25 to ₹6,393 crore. While the company has been outperforming industry growth in the domestic market, it is also planning to increase MR strength by 23 per cent by FY26-end. Torrent has a strong presence in the cardiovascular, gastrointestinal and neurology segments. JB too has prominent cardiac and gastro brands like Cilacar, Metrogyl and Rantac. Torrent is also working on launching GLP-1 products as a day-one launch in FY26. Analysts expect a 15 per cent sales CAGR in domestic formulations for Torrent Pharma over FY25–27. Gaurav Trehan, co-head of Asia Pacific and head of Asia Pacific private equity at KKR, and CEO of KKR India, said: 'JB Pharma's transformation under our stewardship is a testament to KKR's ability to scale high-quality companies.' Nikhil Chopra, chief executive officer and whole-time director of JB Pharma, pointed out that over the past five years, the company has emerged as one of India's fastest-growing pharmaceutical players. 'We have built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organisations will unlock greater opportunities to enhance healthcare access across our markets,' Chopra said. JB Pharma posted 12 per cent revenue growth in FY25 to ₹3,918 crore, while its EBITDA rose 16 per cent to ₹1,087 crore, and PAT increased 19 per cent to ₹660 crore. Notably, KKR Private equity has invested $2 billion in India in 2024 and recently invested $600 million in Manipal Group via its private credit arm.

Contribute to stable borders, Xi tells Tibetans near Arunachal Pradesh
Contribute to stable borders, Xi tells Tibetans near Arunachal Pradesh

Business Standard

timean hour ago

  • Business Standard

Contribute to stable borders, Xi tells Tibetans near Arunachal Pradesh

Chinese President Xi Jinping on Sunday called on the Tibetan residents of a village situated near the Indian border to contribute towards fostering prosperity and stability in the border areas. "Learning that the village has undergone new changes in recent years and villagers' incomes have increased, I feel happy for you," Xi replied to a letter received from residents of Nyingchi, a prefecture-level area located close to the Arunachal Pradesh border. China claims Arunachal Pradesh as part of South Tibet, which is firmly rejected by India. Xi visited Nyingchi in 2021, becoming the only Chinese president to have visited the border areas of Tibet. Xi, in his letter, voiced hope that Nyingchi residents will, under the guidance of the Communist Party's policies to develop border areas and improve people's lives, do an even better job in protecting the natural beauty of the plateau region, developing the village's tourist brand, and contributing to building a prosperous and stable border area. In recent years, China has built a number of villages along the Tibetan border areas to ensure border security and development. In his letter, Xi also urged the people in the Tibet Autonomous Region to uphold ethnic solidarity and create a happier and better life, the state-run Xinhua news agency reported. During his 2021 visit to Nyingchi, Xi visited the Nyang River Bridge to inspect the ecological preservation in the basin of the Brahmaputra River, which is called Yarlung Zangbo in the Tibetan language. Last year, China approved the construction of the world's largest dam, stated to be the planet's biggest infrastructure project, costing $137 billion, on the Brahmaputra river in Tibet, which has raised concerns in the riparian states of India and Bangladesh. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Pharma mergers: Torrent to acquire majority stake in JB Chemicals for Rs 19,500 crore, open offer to follow
Pharma mergers: Torrent to acquire majority stake in JB Chemicals for Rs 19,500 crore, open offer to follow

Time of India

timean hour ago

  • Time of India

Pharma mergers: Torrent to acquire majority stake in JB Chemicals for Rs 19,500 crore, open offer to follow

Torrent Pharmaceuticals on Sunday announced that it will acquire a controlling stake in JB Chemicals & Pharmaceuticals in a Rs 19,500 crore deal, making it India's second most-valued pharma firm by market capitalisation. Torrent will acquire 46.39% stake from the promoters for around Rs 11,917 crore, and an additional 2.80% from certain JB Chemicals employees for Rs 719 crore. Both transactions are being executed at Rs 1,600 per share, according to PTI report. Following this, Torrent will make an open offer for a 26% stake from public shareholders at Rs 1,639.18 per share, totalling Rs 6,842.8 crore, in line with listing regulations. 'This will be the second-largest transaction in the Indian pharma sector,' Torrent Pharma said in a statement, PTI quoted. Torrent Pharmaceuticals and global investment firm KKR jointly announced the deal, which values JB Chemicals at an equity valuation of Rs 25,689 crore on a fully diluted basis. The agreement includes a plan to merge the two entities, the company said. Torrent stated that the acquisition marks a strategic milestone, enabling it to build a future-ready healthcare platform that combines its chronic segment strength with JB Chemicals' presence in international CDMO (contract development and manufacturing organisation) operations Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store